Key Highlights

  • Net loss for the third quarter of 2026 was $21.9 million, compared with $24.3 million a year earlier.
  • Cash and cash equivalents totaled $10.7 million as of September 30, 2026.
  • Year-to-date cash used in Operating Activities fell about 19% year over year.
  • The company expects to exit 2026 at an annualized net cash usage run rate of about $35 million.

Cibus, Inc. (NASDAQ:CBUS) reported financial results for the quarter ended September 30, 2026, and gave a Business update on November 12, 2026. The San Diego company uses biology to produce sustainable ingredients and develops traits intended to help farmers grow crops with fewer inputs. The quarter showed a smaller net loss and lower year-to-date cash use, while the company moved two biofragrance products into Manufacturing and advanced several crop programs with partners.

Financial Results and Cash Position

Cibus reported a net loss of $21.9 million for the quarter, compared with $24.3 million in the same period of 2025. The net loss per share of Class A common stock was $0.29, compared with $0.44 a year earlier. The company said year-to-date cash used in operating activities declined by about 19% from the prior year, and it continues to expect to exit 2026 at an annualized net cash usage run rate of about $35 million.

Cash and cash equivalents were $10.7 million at September 30, 2026. The company said that figure takes into account its implemented cost-saving initiatives but does not include potential financing transactions it may pursue. The release therefore leaves open how the company will fund operations beyond its current cash balance.

Biofragrance and Trait Programs

Cibus said it began manufacturing its first two biofragrance products, and that its customer has requested larger quantities of both to advance product development. The company estimates the biofragrance program represents a peak annual Revenue opportunity of about $100 million, with eight products currently identified for potential commercialization. The figure is an estimate in the release and not a forecast of recognized revenue.

On the crop side, the company said its rice herbicide-tolerance traits performed well in Latin American field trials and are now being tested in its partner Interoc's own rice varieties in field conditions. A second partner-funded program, covering mustard in India, began work during the quarter. Cibus said it continues to advance toward a definitive commercialization agreement with Interoc, which would allow the partner to sell commercial seed carrying Cibus traits.

Sector Context

Gene-editing and biotech-based agriculture companies generally depend on regulatory approvals, partner adoption and access to Capital before their products reach growers at scale. The timing of trait commercialization can be slow, and revenue often arrives in stages through licensing, royalties and milestone payments rather than through steady product sales.

Cibus's model reflects that pattern. Its biofragrance work sits in a separate market from its crop traits, and the company is seeking revenue from both at a time when its cash balance is modest relative to its planned burn. Investors comparing the company with other agricultural technology businesses will need to consider how each stage of its partner pipeline translates into payments.

Risks and What Lies Ahead

The release points to several items that will shape the coming year. The definitive agreement with Interoc, the progress of field trials, the scale of biofragrance orders and the company's ability to finance operations each carry uncertainty. Management's forward-looking statements also note the possibility that partner timelines and regulatory decisions differ from expectations.

Cibus's next updates should show whether the cost reductions hold, whether the biofragrance orders turn into revenue and whether the Interoc arrangement moves to a binding commercial agreement. Those developments will determine how far the company's cash position can carry its current plans.

For investors reading the release, the time frame matters. The company's current cash position and its planned run rate together imply a funding need within the next several quarters, while the partner milestones it has described depend on timelines set by third parties. The release makes clear that the outcome of any financing will affect how quickly the biofragrance and trait programs can advance.

Final Word

The third quarter shows Cibus narrowing its net loss and reducing cash use, while moving its biofragrance and crop programs further along. The company's stated run rate and modest cash balance make its financing plans a central question. Progress toward a commercialization agreement and early biofragrance orders are the developments that will matter most in its upcoming reports.